We are rapidly demystifying cancers, exposing the molecular mechanisms underlying tumors and leading the search for the next generation of targeted cancer therapies. We see a future where every cancer and every patient has a cure.
A major issue in cancer medicine is matching patients with effective treatments. Although patients with colorectal cancer were among the first to receive targeted therapies, many were ineligible, as their cancer-promoting mutations were believed to cause resistance to certain drugs. Assistant Professor Edward Stites and first author Thomas McFall paired computational models and experimental data and discovered that up to 12,000 additional colon cancer patients could benefit from an existing class of targeted therapies. They hope that clinical trials will highlight the magnitude of these findings and motivate more research on these mutations.

Sign up for our monthly newsletter.

Latest discoveries, events & more.